Efeitos da suplementacao de Beta-hidroxi-Beta-metilbutirato na eficiencia mecanica em canoístas de elite / Efectos de suplementación de Beta-hidroxi-Beta-methylbutyrate in mechanical efficiency in elite paddlers / Effects of supplementation Beta-hydroxy-Beta-methylbutyrate in mechanical efficiency in elite paddlers

Objetivo. O presente estudo prospectivo, randomizado, duplo‐cego e placebo‐controlado, verificou o efeito da ingestão de 3g/dia‐1 Beta‐hidroxi‐Beta‐metilbutirato sobre os parâmetros da curva força‐tempo em canoístas de elite. Método. Participaram 24 canoístas, homens, de elite, com 21.41±5.35 anos, 173.36±8.27cm e 69.83±10.29kg. Formaram‐se 2 grupos, um suplementado (HMB) e outro placebo (CON), ambos acompanhados por 14 dias e submetidos a teste máximo de 4min (pré e pós) num caiaque ergômetro. Resultados. Apontam melhora na eficiência mecânica em consonância com o aumento significativo do impulso gerado (17.23%, p=0.02), da potência média (26.6%, p=0.01), frequência de remada (13.5%, p=0.04), perante teste máximo de 4min em ergômetro. Conclusão. Houve melhora na capacidade de gerar potência, que pode estar associada com a suplementação de Beta‐hidroxi‐Beta‐metilbutirato, através da diminuição do catabolismo durante o treinamento; contudo, o mecanismo pelo qual isso pode ocorrer ainda é desconhecido (AU)

Objetivo. Este estudio aleatorizado, doble ciego prospectivo, controlado y placebo, tubo como objetivo comprobar el efecto de la ingesta de 3g/día‐1 de Beta‐hidroxi‐Beta‐metilbutirato en los parámetros de la curva fuerza‐tiempo en kayakistas de élite. Método. Veinticuatro kayakistas, hombres, élite con 21.41±5.35 años, 173.36±8.27cm y 69.83±10.29kg. Formado dos grupos, uno suplementado (HMB) y otro placebo (CON), ambos siguieron durante 14 días y sometido a máxima 4min prueba (pre y post) en un ergómetro kayak. Resultados. Se apreció una mejora en la eficiencia mecánica en relación con el aumento significativo del impulso generado (17.23% p=0.02), la potencia media (26.6% p=0.01), frecuencia de carrera (13.5% p=0.04) durante una prueba máxima en ergómetro de 4min. Conclusión. Hubo una mejora en la capacidad para generar energía, que puede estar asociada con la administración de suplementos de Beta‐hidroxi‐Beta‐metilbutirato mediante la reducción de catabolismo durante el entrenamiento, sin embargo, el mecanismo por el que esto puede ocurrir es aún desconocido (AU)

Objective. This prospective, randomized, double‐blind, placebo‐controlled, checked the effect of the intake of 3g/day‐1 of Beta‐Hidroxy‐Beta‐Methylbutyrato on the parameters of the force‐time curve in elite kayakers. Method. 24 paddlers, men, elite with 21.41±5.35 years, 173.36±8.27cm and 69.83±10.29kg. Formed two groups, one supplemented (HMB) and another placebo (CON), both followed for 14 days and subjected to maximum test 4min (pre and post) in a kayak ergometer. Results. Point improvement in mechanical efficiency in line with the significant increase in the generated pulse (17.23% p=0.02), average power (26.6% p=0.01), stroke frequency (13.5% p=0.04) before maximum test 4min ergometer. Conclusion. There was improvement in the ability to generate power, which may be associated with supplementation of Beta‐Hidroxy‐Beta‐Methylbutyrato by reducing catabolism during training, however the mechanism by which this may occur is still unknown (AU)

Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years.

Respiratory viruses can cause significant morbidity in immunocompromised hosts. Human metapneumovirus (hMPV) has been increasingly associated with lower respiratory tract infection in hematopoietic SCT (HSCT) recipients, with mortality rates up to 50%. No data on the occurrence of hMPV infection in HSCT recipients have been reported in the southern hemisphere. We conducted a retrospective study including 228 nasal wash samples from 153 HSCT recipients with respiratory symptoms during 2001, 2002 and 2003. hMPV was detected by real-time PCR with primers complementary to the nucleocapsid region of hMPV genome. Eleven of the 153 patients (7.2%) acquired hMPV infection during the study period (6.4% in 2001, 4.7% in 2002 and 11.1% in 2003). Among the 11 HSCT recipients with hMPV infection, 1 died 8 days after the diagnosis, but the role of hMPV in the patient's death could not be established. In 2001 and 2003, hMPV group A prevailed over group B. In 2002, both groups were detected equally. hMPV infections were diagnosed in late winter and spring. The frequency of hMPV infection in HSCT recipients living in Brazil was similar to those observed in the northern hemisphere. Sensitive techniques to detect hMPV should be included in the diagnostic assessment of HSCT recipients with respiratory symptoms.

Total agenesis of the left pericardium.

This is the report of a 46-year-old patient with the preoperative diagnosis of an atrial septal defect (ASD) of the ostium secudum type. After sternectomy, partial agenesis of the left pericardium was diagnosed. It is our opinion that, if the radiographic picture is suggestive of this entity, a clinical search for cardiopulmonary anomalies should be performed, because the majority of these associated anomalies can and should be surgically corrected.